Insiders BridgeBio Pharma, Inc.

Equities

Delayed Nasdaq Other stock markets 03:51:57 2024-04-30 pm EDT			5-day change	1st Jan Change
25.88 ^USD	+1.61%		+1.53%	-35.97%

Apr. 07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
Mar. 20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Bridgebio Pharma Insider Sold Shares Worth $4,206,000, According to a Recent SEC Filing	Dec. 28	MT
Bridgebio Pharma Insider Sold Shares Worth $1,500,038, According to a Recent SEC Filing	Nov. 20	MT
Bridgebio Pharma Insider Sold Shares Worth $660,059, According to a Recent SEC Filing	Nov. 20	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: BridgeBio Pharma	23-03-06	MT
BridgeBio Pharma, Inc. Announces Board and Committee Changes	23-02-23	CI
Insider Sell: BridgeBio Pharma	23-02-07	MT
BridgeBio Pharma Executive to Join Atai Life Sciences as CFO	22-06-17	MT
Insider Buy: Bridgebio Pharma	22-01-04	MT
Bridgebio Pharma, Inc. Appoints Hannah Valantine to Its Board of Directors	21-10-25	CI
BridgeBio Pharma, Inc Announces Board Appointments	21-08-24	CI
Bridgebio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to Its Board of Directors	21-08-18	CI
BridgeBio Pharma, Inc. Announces Executive Changes	21-01-04	CI
Bridgebio Pharma Announces the Resignation of Brian Stolz as Chief Operating Officer of the Company	20-10-23	CI
BridgeBio Pharma, Inc. Announces Board Appointments	20-06-24	CI

No results for this search